Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN) is a healthcare company (biotechnology) based in the United States. The share price is $9.76, down 1.61% on the day, which values the company at $624.99M. Price as of 17 Nov 2026, 18:16 UTC, from Yahoo Finance.
Key facts
- Share price
- $9.76−1.61% today
- Market value
- $624.99M
- 200-week average
- $6.4751% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Design Therapeutics, Inc. in more detail
DSGN trades at -6.3× next year's expected earnings. It sits 51% above its 200-week average of $6.47.
In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.
1 of the superinvestors tracked here hold DSGN, including Julian and Felix Baker (0.2% of the portfolio).
Superinvestors holding DSGN
1 of the investors tracked here report a position in their latest 13F filing.
- Julian and Felix Baker Baker Bros. Advisors0.19% of portfolio · $38.8M · added · Q2 2026
Design Therapeutics, Inc. (DSGN): questions and answers
What is Design Therapeutics, Inc.'s market cap?
Design Therapeutics, Inc. is valued at $624.99M at a share price of $9.76.
Is DSGN above its 200-week moving average?
Yes. DSGN is 50.8% above its 200-week average of $6.47. Long-term investors watch that line because strong companies rarely trade below it for long.
Does DSGN pay a dividend?
Design Therapeutics, Inc. does not currently pay a regular dividend.
Which famous investors own DSGN?
In their latest quarterly filings, Julian and Felix Baker (0.2% of the portfolio) hold DSGN. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Design Therapeutics, Inc. (DSGN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/DSGN
Underlying data: Yahoo Finance; company filings with the SEC.